Dataset related to article "A 'Multiomic' Approach of Saliva Metabolomics, Microbiota, and Serum Biomarkers to Assess the Need of Hospitalization in COVID-19"
-
Chiara Pozzi*1
-
Riccardo Levi*2
-
Daniele Braga*1
- Francesco Carli3
- Abbass Darwich2
-
Ilaria Spadoni2
- Bianca Oresta1
- Carola Conca Dioguardi4
- Clelia Peano4
- Leonardo Ubaldi2
- Giovanni Angelotti1
- Barbara Bottazzi1
-
Cecilia Garlanda5
- Antonio Desai5
-
Antonio Voza5
-
Elena Azzolini5
-
Maurizio Cecconi5
- ICH COVID-19 Task-force5
-
Alberto Mantovani6
- Giuseppe Penna1
- Riccardo Barbieri7
-
Letterio S. Politi5
-
Maria Rescigno#5
- 1. IRCCS Humanitas Research Hospital, via Manzoni 56, 20072 Rozzano (Mi) - Italy
- 2. Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele – Milan, Italy
- 3. Department of Informatics, Università degli Studi di Torino, Torino, Piemonte, Italy
- 4. The William Harvey Research Institute, Queen Mary University of London, London, UK
- 5. IRCCS Humanitas Research Hospital, via Manzoni 56,20089 Rozzano (Mi) - Italy AND Humanitas University, Department of Biomedical Sciences, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele – Milan, Italy
- 6. IRCCS Humanitas Research Hospital, via Manzoni 56,20089 Rozzano (Mi) - Italy AND Humanitas University, Department of Biomedical Sciences, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele – Milan, Italy AND The William Harvey Research Institute, Queen Mary University of London, London, UK
- 7. Department of Electronics, Information and Bioengineering, Politecnico di Milano, via Ponzio 34/5 - 20133 Milano, Italy
Description
*These authors contributed equally to the work #Corresponding author
This record contains raw data related to article “A ‘Multiomic’ Approach of Saliva Metabolomics, Microbiota, and Serum Biomarkers to Assess the Need of Hospitalization in COVID-19"
Abstract:
The SARS-CoV-2 pandemic has overwhelmed the treatment capacity of the healthcare systems during the highest viral diffusion rate. Patients reaching the emergency department had to be either hospitalized or discharged. Still, the decision was taken based on the individual assessment of the actual clinical condition, without specific biomarkers to predict future improvement or deterioration. Often discharged patients returned to the hospital for aggravation of their condition. Here we have developed a new combined approach of omics to identify factors that could distinguish COVID-19 inpatients from outpatients. We tested the metabolome in the saliva and identified nine metabolites that separated the inpatient from the outpatient population, but not completely. When combined with serum biomarkers, just two salivary metabolites (myo-inositol and 2-pyrollidine acetic acid) and one serum protein, Chitinase 3-like-1(CHI3L1) were sufficient to separate the two groups completely. These metabolites positively or negatively correlated with four modulated microbiota taxa. This is a proof-of-concept that a combined omic analysis can be used to stratify patients.